User profiles for P. Kuna

Piotr Kuna

Professor of Medicine, Medical University of Lodz, Poland
Verified email at umed.lodz.pl
Cited by 38500

Allergic rhinitis and its impact on asthma (ARIA) 2008

…, O Kalayci, MA Kaliner, YY Kim, ML Kowalski, P Kuna… - Allergy, 2008 - Wiley Online Library
Allergic rhinitis is a symptomatic disorder of the nose induced after allergen exposure by an
immunoglobulin E (IgE)-mediated inflammation of the membranes lining the nose (1). It was …

Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs

…, L Grouse, T Haahtela, N Khaltaev, P Kuna… - Journal of Allergy and …, 2012 - Elsevier
Allergic rhinitis (AR) and asthma represent global health problems for all age groups.
Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on …

Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development …

…, O Kalayci, JK Tebbe, ML Kowalski, P Kuna… - Journal of Allergy and …, 2020 - Elsevier
The selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease
and depends on many factors. Grading of Recommendations Assessment, Development …

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision

…, PW Hellings, L Klimek, S Kowalski, P Kuna… - Journal of Allergy and …, 2017 - Elsevier
Background Allergic rhinitis (AR) affects 10% to 40% of the population. It reduces quality of
life and school and work performance and is a frequent reason for office visits in general …

[HTML][HTML] Oral glucocorticoid–sparing effect of benralizumab in severe asthma

…, A Bourdin, NL Lugogo, P Kuna, P Barker… - New England journal …, 2017 - Mass Medical Soc
… in the oral glucocorticoid doses in the placebo group (P<0.001 for both comparisons). The
odds of … 1.83, P=0.003), and benralizumab administered every 8 weeks resulted in an annual …

International consensus on (ICON) pediatric asthma

…, O Kalayci, N Aït‐Khaled, S Kling, P Kuna… - Allergy, 2012 - Wiley Online Library
Asthma is the most common chronic lower respiratory disease in childhood throughout the
world. Several guidelines and/or consensus documents are available to support medical …

Sub-Lingual Immunotherapy: World Allergy Organization Position Paper 2009

…, L Fontana, CH Katelaris, R Kaulsay, P Kuna… - World Allergy …, 2009 - Springer
Sublingual immunotherapy (SLIT) has gained wide accep-tance in many European countries
and has raised the level of interest in immunotherapy among practicing allergists and …

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

…, P Staubach, T Jakob, RG Stirling, P Kuna… - Journal of Allergy and …, 2013 - Elsevier
… Treatment differences were presented as least squares means (LSMs), along with
corresponding 95% CIs and P values. Analysis of additional end points evaluating change from …

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations

P Kuna, MJ Peters, AI Manjra, C Jorup… - … journal of clinical …, 2007 - Wiley Online Library
This randomised, double‐blind, 6‐month study compared budesonide/formoterol for
maintenance and relief with salmeterol/fluticasone and a fixed maintenance dose of budesonide/…

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

…, ER Bleecker, E Pizzichini, P Kuna… - The Lancet …, 2014 - thelancet.com
Background Persistent eosinophilic airway inflammation in asthma increases the risk of
exacerbations. In a phase 2b dose-ranging study, we aimed to assess the efficacy and safety of …